Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis P Garrison

Showing results (81-90 of 190) with videos related to

Pageof 19
Sort By:
Vaccines|May 25, 2017
The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United StatesBlythe J S Adamson, Josh J Carlson, James G Kublin, et al.
Pharmacoeconomics|June 9, 2023
Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key DriversAurelie Meunier, Louise Longworth, Manuel Gomes, et al.
Journal of Managed Care & Specialty Pharmacy|August 3, 2015
Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT)William J Canestaro, Daryl E Pritchard, Louis P Garrison, et al.
Cancer|June 27, 2007
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancerLouis P Garrison, Deborah Lubeck, Deepa Lalla, et al.
Applied Health Economics and Health Policy|March 26, 2014
Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturersJosh J Carlson, Katharine S Gries, Kai Yeung, et al.
Rheumatology and Therapy|January 14, 2017
Estimating the Cost of Illness of Giant Cell Arteritis in the United StatesJoseph B Babigumira, Meng Li, Denise M Boudreau, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 3, 2010
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practiceDavid L Veenstra, Joshua A Roth, Louis P Garrison, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 19, 2026
Towards a Vision for HEOR: From Technology Appraisal to Health Policy ScienceNewell E McElwee, Richard J Willke, Stephanie Earnshaw, et al.
Journal of Medical Economics|December 15, 2021
Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trialJipan Xie, Yan Wang, Yaping Xu, et al.
Journal of Evaluation in Clinical Practice|October 21, 2016
A proposed approach for quantitative benefit-risk assessment in diagnostic radiology guideline development: the American College of Radiology Appropriateness Criteria ExampleMaria Agapova, Brian B Bresnahan, Mitchell Higashi, et al.
Pageof 19

Showing results (81-90 of 190) with videos related to

Sort By:
Pageof 19
Vaccines|May 25, 2017
The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United StatesBlythe J S Adamson, Josh J Carlson, James G Kublin, et al.
Pharmacoeconomics|June 9, 2023
Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key DriversAurelie Meunier, Louise Longworth, Manuel Gomes, et al.
Journal of Managed Care & Specialty Pharmacy|August 3, 2015
Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT)William J Canestaro, Daryl E Pritchard, Louis P Garrison, et al.
Cancer|June 27, 2007
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancerLouis P Garrison, Deborah Lubeck, Deepa Lalla, et al.
Applied Health Economics and Health Policy|March 26, 2014
Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturersJosh J Carlson, Katharine S Gries, Kai Yeung, et al.
Rheumatology and Therapy|January 14, 2017
Estimating the Cost of Illness of Giant Cell Arteritis in the United StatesJoseph B Babigumira, Meng Li, Denise M Boudreau, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 3, 2010
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practiceDavid L Veenstra, Joshua A Roth, Louis P Garrison, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 19, 2026
Towards a Vision for HEOR: From Technology Appraisal to Health Policy ScienceNewell E McElwee, Richard J Willke, Stephanie Earnshaw, et al.
Journal of Medical Economics|December 15, 2021
Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trialJipan Xie, Yan Wang, Yaping Xu, et al.
Journal of Evaluation in Clinical Practice|October 21, 2016
A proposed approach for quantitative benefit-risk assessment in diagnostic radiology guideline development: the American College of Radiology Appropriateness Criteria ExampleMaria Agapova, Brian B Bresnahan, Mitchell Higashi, et al.
Pageof 19